Physician profile
John E Vernon
NPI 1891793105
$5,341.78
in general payments reported to CMS, 2019-2025
36 companies · $703 in 2025
The $703 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $425 · 2021: $779 · 2022: $1,076 · 2023: $591 · 2024: $662 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,955.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,324.75 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $689.62 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $473.55 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $369.01 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $254.84 | 2019-2025 | Repatha, Otezla |
| Pfizer INC. | $251.87 | 2019-2025 | |
| Exact Sciences Corporation | $249.04 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $229.64 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $158.50 | 2019-2022 | |
| Glaxosmithkline, LLC. | $137.16 | 2019-2025 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.92 | 2019-2023 | Jardiance |
| Arbor Pharmaceuticals, INC. | $111.86 | 2019-2021 | |
| Amarin Pharma, INC. | $110.98 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.44 | 2019-2024 | Xifaxan, Ibschek |
| Merck Sharp & Dohme LLC | $103.24 | 2020-2021 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vernon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.